

---

# LITERATURA K ILUSTRACÍM

## Základní monografie

1. Gomperts B, Kramer I, Tatham P. Signal Transduction. 2nd Edition. Cambridge (Massachusetts): Academic Press; 2009.
2. Murphy K. Janeway's immunobiology. 8th ed. London: Garland Science; 2012.
3. Nelson J. Structure and Function in Cell Signalling. Chichester: Wiley-Blackwell; 2008.
4. Petsko G, Ringe D. Protein Structure and Function. London: New Science Press; 2004.
5. Stříž I, Holář V. Cytokiny v klinické medicíně. Praha: Maxdorf; 2015.
6. Zdražil J, Horák P, Karásek D. Moderní farmakoterapie autoimunitních chorob. Praha: Maxdorf; 2015.

## Další použitá literatura

1. Agarwal SM, Pal D, Gupta M, Saini R. Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants. *Curr Cancer Drug Targets*. 2017;17(7):617–636.
2. Blanc J, Geney R, Menet C. Type II kinase inhibitors: an opportunity in cancer for rational design. *Anticancer Agents Med Chem*. 2013 Jun;13(5):731–47.
3. Boussiotis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. *N Engl J Med*. 2016 Nov 3;375(18):1767–1778.
4. Ciombor KK, Berlin J. Aflibercept—a decoy VEGF receptor. *Curr Oncol Rep*. 2014 Feb;16(2):368.
5. Collins I, Wang H, Caldwell JJ, Chopra R. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway. *Biochem J*. 2017 Mar 15;474(7):1127–1147.
6. Cooper C. Oncogene MET – name origin. Osobní komunikace.
7. Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, et al. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. *Proc Natl Acad Sci U S A*. 2015 Sep 29;112(39):E5381–90.
8. Davies TG, Tunnah P, Meijer L, Marko D, Eisenbrand G, Endicott JA, et al. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. *Structure*. 2001 May 9;9(5):389–97.
9. Day PJ, Cleasby A, Tickle IJ, O'Reilly M, Coyle JE, Holding FP, et al. Crystal structure of human CDK4 in complex with a D-type cyclin. *Proc Natl Acad Sci U S A*. 2009 Mar 17;106(11):4166–70.
10. Diekman AB, Norton EJ, Klotz KL, Westbrook VA, Shibahara H, Naaby-Hansen S, et al. N-linked glycan of a sperm CD52 glycoform associated with human infertility. *FASEB J*. 1999 Aug;13(11):1303–13.
11. Eckstein N, Röper L, Haas B, Potthast H, Hermes U, Unkrig C, et al. Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. *J Exp Clin Cancer Res*. 2014 Feb 7;33:15.
12. Fabbro D. 25 years of small molecular weight kinase inhibitors: potentials and limitations. *Mol Pharmacol*. 2015 May;87(5):766–75.
13. Fait T, Zikán M, Mašata J, et al. Moderní farmakoterapie v gynekologii a porodnictví. Praha: Maxdorf; 2014.

14. Fischer ES, Böhm K, Lydeard JR, Yang H, Stadler MB, Cavadini S, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. *Nature*. 2014 Aug 7;512(7512):49–53.
15. Freeman GJ. Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. *Proc Natl Acad Sci U S A*. 2008 Jul 29;105(30):10275–6.
16. Fuchs O, Bokorová R, Vostrý M, Kostečka A, Polák J. Cereblon and Its Role in the Treatment of Multiple Myeloma by Lenalidomide or Pomalidomide. *International Journal of Hematological Disorders*, 2014, Vol. 1, No. 1A, 13–20.
17. Ghose AK, Herbertz T, Pippin DA, Salvino JM, Mallamo JP. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. *J Med Chem*. 2008 Sep 11;51(17):5149–71.
18. Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. *Oncologist*. 2010;15(6):539–47.
19. Hána V. *Endokrinologie pro praxi*. Praha: Maxdorf; 2014.
20. Hantschel O. Structure, regulation, signaling, and targeting of abl kinases in cancer. *Genes Cancer*. 2012 May;3(5–6):436–46.
21. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. *Gut*. 1994;35(3 Suppl):S1–4.
22. Hartmann MD, Boichenko I, Coles M, Zanini F, Lupas AN, Hernandez Alvarez B. Thalidomide mimics uridine binding to an aromatic cage in cereblon. *J Struct Biol*. 2014 Dec;188(3):225–32.
23. Heinrich MC, Marino-Enriquez A, Presnell A, Donsky RS, Griffith DJ, McKinley A, et al. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. *Mol Cancer Ther*. 2012 Aug;11(8):1770–80.
24. Hennessey KM, Smith TR, Xu JW, Alas GC, Ojo KK, Merritt EA, et al. Identification and Validation of Small-Gatekeeper Kinases as Drug Targets in *Giardia lamblia*. *PLoS Negl Trop Dis*. 2016 Nov 2;10(11):e0005107.
25. Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. *Science*. 2017 Mar 31;355(6332):1428–1433.
26. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. *Clin Pharmacokinet*. 1993 Nov;25(5):375–91.
27. Chen L, Fu W, Zheng L, Liu Z, Liang G. Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer. *J Med Chem*. 2018 May 24;61(10):4290–4300.
28. Ito T, Handa H. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. *Int J Hematol*. 2016 Sep;104(3):293–9.
29. Jeffrey PD, Tong L, Pavletich NP. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. *Genes Dev*. 2000 Dec 15;14(24):3115–25.
30. Kirby IT, Cohen MS. Small-Molecule Inhibitors of PARPs: From Tools for Investigating ADP-Ribosylation to Therapeutics. *Curr Top Microbiol Immunol*. 2019;420:211–231.
31. Ko B, Paucar D, Halmos B. EGFR T790M: revealing the secrets of a gatekeeper. *Lung Cancer (Auckl)*. 2017 Oct 9;8:147–159.
32. Kolek V, Kašák V, Vašáková M et al. *Pneumologie 3rd ed*. Praha: Maxdorf; 2017.
33. Law ME, Corsino PE, Narayan S, Law BK. Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics. *Mol Pharmacol*. 2015 Nov;88(5):846–52.
34. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. *Sci Rep*. 2017 Jul 17;7(1):5532.
35. Li XN, Rao T, Xu YF, Hu KR, Zhu ZP, Li HF, et al. Pharmacokinetic and pharmacodynamic evidence for developing an oral formulation of octreotide against gastric mucosal injury. *Acta Pharmacol Sin*. 2018 Aug;39(8):1373–1385.
36. Li Y, Zhang J, Gao W, Zhang L, Pan Y, Zhang S, et al. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2. *Int J Mol Sci*. 2015 Apr 24;16(5):9314–40.
37. Liu Q, Kriksunov IA, Graeff R, Munshi C, Lee HC, Hao Q. Crystal structure of human CD38 extracellular domain. *Structure*. 2005 Sep;13(9):1331–9.

38. Liu W, Ning JF, Meng QW, Hu J, Zhao YB, Liu C, et al. Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent. *Drug Des Devel Ther.* 2015 Jul 23;9:3837–51.
39. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. *Blood.* 2011 Sep 29;118(13):3470–8.
40. Mariaule G, Belmont P. Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey. *Molecules.* 2014 Sep 11;19(9):14366–82.
41. Medves S, Demoulin JB. Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. *J Cell Mol Med.* 2012 Feb;16(2):237–48.
42. Mitsiades CS. How „immunomodulatory“ are IMiDs? *Blood.* 2011 Feb 3;117(5):1440–1.
43. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. *Aliment Pharmacol Ther.* 2010 Jan 15;31(2):169–88.
44. Najjar A, Platzer C, Luft A, Aßmann CA, Elghazawy NH, Erdmann F, et al. Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1. *Eur J Med Chem.* 2019 Jan 1;161:479–492.
45. Nooka A, Gleason C, Casbourne D, Lonial S. Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. *Biologics.* 2013;7:13–32.
46. Nussinov R, Zhang M, Tsai CJ, Liao TJ, Fushman D, Jang H. Autoinhibition in Ras effectors Raf, PI3K $\alpha$ , and RASSF5: a comprehensive review underscoring the challenges in pharmacological intervention. *Biophys Rev.* 2018 Oct;10(5):1263–1282.
47. O'Bryan JP, Frye RA, Cogswell PC, et al. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. *Mol Cell Biol.* 1991 Oct;11(10):5016–31.
48. Ou SH, Tan J, Yen Y, Soo RA. ROS1 as a „druggable“ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. *Expert Rev Anticancer Ther.* 2012 Apr;12(4):447–56.
49. Reckel S, Gehin C, Tardivon D, Georgeon S, Kükenshöner T, Löhr F, et al. Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase. *Nat Commun.* 2017 Dec 13;8(1):2101.
50. Reshetnyak AV, Nelson B, Shi X, Boggon TJ, Pavlenco A, Mandel-Bausch EM, et al. Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region. *Proc Natl Acad Sci U S A.* 2013 Oct 29;110(44):17832–7.
51. Rodríguez-Alba JC, Moreno-García ME, Sandoval-Montes C, Rosales-García VH, Santos-Argumedo L. CD38 induces differentiation of immature transitional 2 B lymphocytes in the spleen. *Blood.* 2008 Apr 1;111(7):3644–52.
52. Roskoski R Jr. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. *Pharmacol Res.* 2016 Jan;103:26–48.
53. Roskoski R Jr. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. *Pharmacol Res.* 2017 Jul;121:202–212.
54. Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. *Pharmacol Res.* 2019 Jan;139:395–411.
55. Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. *Ann Oncol.* 2018 Jan 1;29(1):71–83.
56. Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. *J Hematol Oncol.* 2016 Jun 30;9(1):51.
57. Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. *J Hematol Oncol.* 2013 Sep 30;6(1):74.
58. Shi Q, Chen L. Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation. *J Immunol Res.* 2017;2017:9130608.
59. Shibuya M. VEGF-VEGFR Signals in Health and Disease. *Biomol Ther (Seoul).* 2014 Jan;22(1):1–9.
60. Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. *Ther Adv Urol.* 2012 Aug;4(4):167–78.
61. Smith S, Keul M, Engel J, Basu D, Eppmann S, Rauh D. Characterization of Covalent-Reversible EGFR Inhibitors. *ACS Omega.* 2017 Apr 30;2(4):1563–1575.

62. Sng JC, Taniura H, Yoneda Y. A tale of early response genes. *Biol Pharm Bull.* 2004 May;27(5):606–12.
63. Somoza JR, Koditek D, Villaseñor AG, Novikov N, Wong MH, Liclican A, et al. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase  $\delta$ . *J Biol Chem.* 2015 Mar 27;290(13):8439–46.
64. Štětkářová I, et al. *Moderní farmakoterapie v neurologii.* 2nd ed. Praha: Maxdorf; 2017.
65. Tadesse S, Yu M, Kumarasiri M, Le BT, Wang S. Targeting CDK6 in cancer: State of the art and new insights. *Cell Cycle.* 2015;14(20):3220–30.
66. Tan S, Chen D, Liu K, He M, Song H, Shi Y, et al. Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. *Protein Cell.* 2016 Dec;7(12):866–877.
67. Tanaka K. The proteasome: overview of structure and functions. *Proc Jpn Acad Ser B Phys Biol Sci.* 2009;85(1):12–36.
68. Tell V, Hilgeroth A. Recent developments of protein kinase inhibitors as potential AD therapeutics. *Front Cell Neurosci.* 2013 Nov 19;7:189.
69. Tesař V, Vachek J, et al. *Moderní farmakoterapie v nefrologii.* Praha: Maxdorf; 2018.
70. Thaimattam R, Banerjee R, Miglani R, Iqbal J. Protein kinase inhibitors: structural insights into selectivity. *Curr Pharm Des.* 2007;13(27):2751–65.
71. Vašáková M et al. *Moderní farmakoterapie v pneumologii.* Praha: Maxdorf; 2013.
72. Vavalà T, Novello S. Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy. *Ther Adv Med Oncol.* 2018 Aug 3;10:1758835918789364.
73. Vladimír Tesař, Jan Vachek a kol. *Moderní farmakoterapie v nefrologii.* Praha: Maxdorf; 2018.
74. Voigt M, Braig F, Göthel M, Schulte A, Lamszus K, Bokemeyer C, et al. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. *Neoplasia.* 2012 Nov;14(11):1023–31.
75. Vokurka M, Hugo J et al. *Velký lékařský slovník, 10th ed.* Praha: Maxdorf; 2015.
76. Wang LH. Oncogene ROS – name origin. *Osobní komunikace.*
77. Wang Z, Canagarajah BJ, Boehm JC, Kassisà S, Cobb MH, Young PR, et al. Structural basis of inhibitor selectivity in MAP kinases. *Structure.* 1998 Sep 15;6(9):1117–28.
78. Yang Q, Modi P, Newcomb T, Quéva C, Gandhi V. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. *Clin Cancer Res.* 2015 Apr 1;21(7):1537–42.
79. Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, et al. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. *Structure.* 2015 Dec 1;23(12):2341–2348.
80. Zhang H, Wang J, Shen Y, Wang HY, Duan WM, Zhao HY, et al. Discovery of 2, 4, 6-trisubstituted pyrido[3, 4-d]pyrimidine derivatives as new EGFR-TKIs. *Eur J Med Chem.* 2018 Mar 25;148:221–237.
81. Zhang H, Wang J, Zhao HY, Yang XY, Lei H, Xin M, et al. Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3, 4-d]pyrimidine scaffold. *Bioorg Med Chem.* 2018 Jul 23;26(12):3619–3633.
82. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. *Nat Rev Cancer.* 2009 Jan;9(1):28–39.
83. Zhao HL, Yang F, Huang X, Zhou QH. Overview of fundamental study of pazopanib in cancer. *Thorac Cancer.* 2014 Nov;5(6):487–93.
84. Zhou N, Gutierrez-Uzquiza A, Zheng XY, Chang R, Vogl DT, Garfall AL, et al. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation. *Leukemia.* 2019 Feb 13.
85. Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. *Leuk Lymphoma.* 2013 Apr;54(4):683–7.
86. Zhu YX, Shi CX, Bruins LA, Wang X, Riggs DL, Porter B, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. *Blood Cancer J.* 2019 Feb 11;9(2):19.